Dr. Joseph Clark, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Loyola University Chicago Stritch School Of Medicine

  Medical School, 1989

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts National Harbor, MD, USA. 9-13 November 2016, 2016-12-08

• Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma, 2015-11-04

• The High-Dose Aldesleukin "Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma, 2014-11-25

• A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): SWOG study S0329, 2014-01-29

• A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma, 2018-07-27

• Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face, 2015-10-04

• Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2), 2015-11-04

• PHASE I ADJUVANT RADIATION WITH DOCETAXEL IN HIGH RISK HEAD AND NECK CANCER, 2014-05-18

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM, 2016-10-29

• An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0, 2018-05-30

• Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF mutated melanoma: a randomized phase 2 trial, 2020-10-05

• The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study, 2015-11-04

• Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report, 2018-06-14

• Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2, 2015-11-04

• Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma, 2016-10-06

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Phase II Study of the Src Kinase Inhibitor Saracatinib (AZD0530) in Metastatic Melanoma, 2012-11-15

• Complications of sequential immunotherapy in metastatic melanoma, 2015-11-04

• Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSMregistry, 2017-12-19